Rep. Carolyn Maloney (D-NY) (Bill Clark/CQ Roll Call via AP Images)

House, Sen­ate Dems in­tro­duce leg­is­la­tion to com­bat 'abu­sive' phar­ma busi­ness prac­tices

In the af­ter­math of Con­gress in­tro­duc­ing leg­is­la­tion al­low­ing Medicare to ne­go­ti­ate drug prices — which cur­rent­ly re­mains in lim­bo af­ter the failed pas­sage of the Build Back Bet­ter Act — some con­gres­sion­al Dems have shift­ed gears and have put their tar­gets on oth­er phar­ma busi­ness prac­tices.

House Over­sight Com­mit­tee Chair Car­olyn Mal­oney led a group of De­mo­c­rat col­leagues and in­tro­duced three bills on Thurs­day to tar­get “busi­ness prac­tices phar­ma­ceu­ti­cal com­pa­nies use to sup­press com­pe­ti­tion, main­tain mar­ket mo­nop­o­lies, and keep drug prices high,” a state­ment from the of­fi­cials said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.